Skip to Main Content

Paper Details

Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.
JACC Heart Fail
5
2023
CRM, CRM conditions, CRM multimorbidity, Cardio-renal-metabolic (CRM) conditions, Dapagliflozin, HF, Heart Failure, Patients, atherosclerotic cardiovascular disease, cardiovascular death, chronic kidney disease, dapagliflozin, heart failure, participants, patients, type 2 diabetes
Author NameAffiliation
Akshay S DesaiBrigham and Women's Hospital, Harvard Medical School
Mikhail KosiborodSaint Luke's Mid America Heart Institute, University of Missouri-Kansas City
Carolyn S P LamNational Heart Centre Singapore and Duke-National University of Singapore
Rudolf A de BoerErasmus Medical Center
Adrian F HernandezDuke University, USA Duke Clinical Research Institute
  • 1 - 5

Datasets

Release 1.2